Analysts expect Nanobiotix S.A. to report revenue of 28.43 M for 2026, against a range of 27.21 M to 29.66 M. The most recent reported year, 2025, came in at 37.88 M, a 14.2% miss against the 44.17 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.95 M | 5.24 M | 38.79 M | -8.00 M | 37.88 M | - | - | ||
| High Estimate | 8.75 M | 2.77 M | 21.60 M | 24.19 M | 48.50 M | 29.66 M | 73.94 M | ||
| Low Estimate | 7.32 M | 2.59 M | 19.78 M | 21.38 M | 39.84 M | 27.21 M | 61.75 M | ||
| Consensus Estimate | 8.04 M | 2.68 M | 20.69 M | 22.78 M | 44.17 M | 28.43 M | 67.84 M |
Analysts expect Nanobiotix S.A. to report earnings per share of -0.59 for 2026, against a range of -0.62 to -0.56. The most recent reported year, 2025, came in at -0.58, a 205.3% miss against the -0.19 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.50 | -1.80 | -1.16 | -1.60 | -0.58 | - | - | ||
| High Estimate | -1.72 | -1.56 | -1.31 | -1.11 | -0.18 | -0.56 | -0.19 | ||
| Low Estimate | -2.02 | -1.68 | -1.47 | -1.21 | -0.20 | -0.62 | -0.23 | ||
| Consensus Estimate | -1.87 | -1.62 | -1.39 | -1.16 | -0.19 | -0.59 | -0.21 |
Pull Wall Street consensus for Nanobiotix S.A. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NBTX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NBTX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NBTX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();